2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1364

Affect of Obesity on Multi-Biomarker Disease Activity (MBDA) Measurements in Rheumatoid Arthritis (RA) Patients
Abstract Number: 1365

Construct Validation of PROMIS Short Form and Profile-29 T-Scores with SF-36 in Rheumatoid Arthritis Patients Treated for 1 Year: Results from a Real World Evidence-Based Study in the United States
Abstract Number: 1366

Self-joint Counts by People with Rheumatoid Arthritis: Does a Video Increase Accuracy and Does It Matter?
Abstract Number: 1367

An Engineered Glove for the Computerised Quantification of Hand Disability in Rheumatoid Arthritis
Abstract Number: 1368

One Size Fits All : Replacing ESR by γGT in DAS28 Calculation Permits a Dual Evaluation of Joint Activity Together with Cardiovascular Risk
Abstract Number: 1369

Angiogenic Factors for Assessing Rheumatoid Arthritis in the Era of Sonographic Diagnosis and Biologic Therapy
Abstract Number: 1370

Not All Joints Are Equal: Challenge DAS28 System and Identify Factors Leading to a Mismatch Between T2T and HAQ Among RA Patients Through Data Mining from Smart System of Disease Management (SSDM)
Abstract Number: 1371

Create an Algorithm of Outcome Forecasting and Decision Making for RA Treatment: Data Mining and Machine Learning via the Smart System of Disease Management (SSDM)
Abstract Number: 1372

Adherence to Treatment with Intravenous Biological Agents in Patients with Rheumatoid Arthritis
Abstract Number: 1373

Performance of CQR5 vs CQR19 in the Evaluation of Adherence to Tofacitinib in Daily Clinical Practice
Abstract Number: 1374

Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Abstract Number: 1375

Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study
Abstract Number: 1376

Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials
Abstract Number: 1377

MTX Withdrawal in Patients with RA Who Achieve Low Disease Activity with Tofacitinib Modified-Release 11 Mg Once Daily + MTX: An Assessment of the Impact on the Short Form-36 Patient-Reported Outcome
Abstract Number: 1378

High Baseline Serum IL-6 Predicts Increased Sarilumab Treatment Response for Patient Reported Symptoms and Health-Related Quality of Life Among Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].